Trials / Completed
CompletedNCT00641979
New Nasal Applicator / New Formulation - User Study
A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Safety, and Functionality of a New Nasal Device With Reformulated Rhinocort Aqua (Budesonide) Versus the Current Product and Versus Placebo in Subjects With Seasonal Allergic Rhinitis (SAR).
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 6 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the efficacy of once daily dosing with Rhinocort Aqua (new formulation) against Rhinocort Aqua (current formulation) and placebo in reliving the symptoms of seasonal allergic rhinitis (SAR).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | budesonide | Current product |
| DEVICE | Budesonide | New type device |
| DRUG | Placebo |
Timeline
- Start date
- 2002-04-01
- Primary completion
- 2002-08-01
- Completion
- 2002-08-01
- First posted
- 2008-03-24
- Last updated
- 2011-01-24
Source: ClinicalTrials.gov record NCT00641979. Inclusion in this directory is not an endorsement.